OPEN END-TURBO-OPTIONSSCHEIN - NOVO NORDISK ADR B | Real-time BOERSE MUENCHEN 09:07:33 03/07/2024 pm IST | ||
| 17.03 EUR | -6.22% |
|
| Current month | -0.55% | ||
| 1 month | +10.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 17.03 | -6.22% |
| 02/24/02 | 18.16 | -2.89% |
| 01/24/01 | 18.7 | +2.41% |
| 28/24/28 | 18.26 | -1.35% |
| 27/24/27 | 18.51 | +0.27% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 09:07 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | HSBC |
| WKN | TT94EA |
| ISIN | DE000TT94EA0 |
| Date issued | 12/11/2021 |
| Strike | 45.57 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 3.13 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.2 € |
|---|---|
| Lowest since issue | 1.24 € |
| Spread | 0.02 € |
| Spread % | 0.12% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- Certificat
